Panacea Biotec is gearing up to launch its dengue vaccine in the next 2-3 years, according to the company’s Chairman and Managing Director, Dr. Rajesh Jain. The vaccine, developed in collaboration with ICMR, is currently progressing through phase three clinical trials across 19 sites in India, covering over 10,000 adults.
In an exclusive interview with CNBC-TV18, Dr. Jain shared that the vaccine has been making significant strides, with clinical trials beginning on August 14, 2024. He expects the vaccine to be launched within two years, pending regulatory approval. Panacea Biotec’s efforts aim to introduce India’s first dengue vaccine, contributing significantly to the country’s healthcare sector.
